MAPK8 and breast carcinoma: Hence, we aim to use anisomycin, a potent activator of JNK, to (1) examine the role played by JNK in breast cancer cells and (2) analyze the expression of p-JNK in breast malignant transformation and in breast cancer patients with clinical follow-up.